BullFrog AI CEO Vin Singh: Using AI to Transform Drug Discovery and Cut Development Costs

In this exclusive interview, BullFrog AI (Nasdaq: BFRG) CEO Vin Singh discusses how the company’s proprietary bfLEAP™ AI platform and BullFrog Data Networks™ are redefining the economics of drug discovery and development.💡 Key Highlights from the Interview:• Exclusive Data Access: Collaborations with the Lieber Institute for Brain Development and J. Craig Venter Institute provide unmatched datasets driving new discoveries in neuropsychiatric and oncology research.• Commercial Traction: Strategic partnership with Sygnature Discovery enables global sales of BullFrog Data Networks, with up to $30M in projected revenue over 3 years.• Operational Efficiency: Lean model burning just $6M annually while advancing multiple revenue-generating programs.• Clinical Validation: Recent success in a Phase 3 oncology study with Eleison Pharmaceuticals demonstrates the power of BullFrog AI’s technology in optimizing clinical trials.• bfPREP™ Launch: New data preparation module accelerates clinical trial readiness by transforming unstructured data into AI-ready formats in days.Subscribe for more deep dives into microcap and smallcap investing. Don’t forget to like the video and hit the notification bell so you never miss an update!Bullfrog AI is a client of RedChip. To learn more about BFRG and to read our full disclosure, visit: BFRGinfo.com.#BFRG #BiotechStocks #AI #DrugDiscovery #ClinicalTrials #Investing #HealthcareInnovation #SmallCapStocks #AIinBiotech